Veralto
VERALTO CORPORATION
Key figures
Period Jan 2025 to Dec 2025ConsolidatedU.S. GAAP
RevenueDisclosed
US$5.5B
Operating marginCalculated
23.2%
Net assets to total assetsCalculated
40.4%
Company profile
Tables scroll sideways
Disclosed data
Profitability
★★★★★position among all companies
23.2%
Growth (revenue, 4-year average)
★★★☆☆position among all companies
4.0%
Capital efficiency
★★★★★position among all companies
30.3%
Revenue and profit
Performance, financial position and capital allocation
Veralto
Recent performance trends
Veralto
Cash flow trends
Consolidated indicators (9 items)
| Item | 4 years ago | 3 years ago | 2 years ago | Last year | This year |
|---|---|---|---|---|---|
| Net sales | US$4.7 billion | US$4.9 billion | US$5.0 billion | US$5.2 billion | US$5.5 billion |
| Operating income | US$1.0 billion | US$1.1 billion | US$1.1 billion | US$1.2 billion | US$1.3 billion |
| Net income | US$0.9 billion | US$0.8 billion | US$0.8 billion | US$0.8 billion | US$0.9 billion |
| Total assets | US$4.8 billion | US$4.8 billion | US$5.7 billion | US$6.4 billion | US$7.7 billion |
| Shareholders' equity | Could not be retrieved | US$3.2 billion | US$1.4 billion | US$2.0 billion | US$3.1 billion |
| Net cash provided by (used in) operating activities | US$0.9 billion | US$0.9 billion | US$1.0 billion | US$0.9 billion | US$1.1 billion |
| Net cash provided by (used in) investing activities | US$-97.00 million | US$-89.00 million | US$-55.00 million | US$-0.4 billion | US$-98.00 million |
| Net cash provided by (used in) financing activities | US$-0.8 billion | US$-0.8 billion | US$-0.1 billion | US$-65.00 million | US$-0.1 billion |
| Cash and cash equivalents | Could not be retrieved | US$0 | US$0.8 billion | US$1.1 billion | US$2.0 billion |
Revenue scale in the same industry
Veralto
Instruments and medical devices: 43 companies · revenue · largest first・each company’s latest fiscal year・Consolidated・Disclosed
- 1 Thermo Fisher ScientificFY Dec 2025 US$44.6B
- 2 Northrop Grumman Corp /DE/FY Dec 2025 US$42.0B
- 3 MedtronicFY Apr 2026 US$36.4B
- … 21 companies
- 25 Edwards LifesciencesFY Dec 2025 US$6.1B
- 26 ResMedFY Jun 2026 US$5.7B
- 27 VeraltoThis companyFY Dec 2025 US$5.5B
- 28 Keysight TechnologiesFY Oct 2025 US$5.4B
- 29 DexcomFY Dec 2025 US$4.7B
- … 14 companies
Sources and methodology
Basic indicators
| Item | Value | Consolidated / Non-consolidated | Source |
|---|---|---|---|
| Purchase of property, plant and equipment | US$63.00 million | Consolidated | Disclosed |
| Cash and cash equivalents | US$2.0 billion | Consolidated | Disclosed |
| Net cash provided by (used in) financing activities | US$-0.1 billion | Consolidated | Disclosed |
| Net cash provided by (used in) investing activities | US$-98.00 million | Consolidated | Disclosed |
| Net cash provided by (used in) operating activities | US$1.1 billion | Consolidated | Disclosed |
| Depreciation and amortization | US$78.00 million | Consolidated | Disclosed |
| Dividends paid | US$0.1 billion | Consolidated | Disclosed |
| Stockholders' equity (including non-controlling interests) | US$3.1 billion | Consolidated | Disclosed |
| Non-controlling interests | US$1.00 million | Consolidated | Disclosed |
| Net assets | US$3.1 billion | Consolidated | Disclosed |
| Net sales | US$5.5 billion | Consolidated | Disclosed |
| Operating income | US$1.3 billion | Consolidated | Disclosed |
| Net income | US$0.9 billion | Consolidated | Disclosed |
| Total assets | US$7.7 billion | Consolidated | Disclosed |
| Operating margin | 23.2% | Consolidated | Calculated |
| Net assets to total assets | 40.4% | Consolidated | Calculated |
| Net margin | 17.1% | Consolidated | Calculated |
| Return on equity | 30.3% | Consolidated | Calculated |